- Home
- BEST vs IMMX Comparison
BEST vs IMMX Comparison
Compare BEST & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEST
- IMMX
- Stock Information
- Founded
- BEST 2007
- IMMX 2014
- Country
- BEST China
- IMMX United States
- Employees
- BEST N/A
- IMMX N/A
- Industry
- BEST
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BEST
- IMMX Health Care
- Exchange
- BEST Nasdaq
- IMMX Nasdaq
- Market Cap
- BEST 55.9M
- IMMX 55.3M
- IPO Year
- BEST N/A
- IMMX 2021
- Fundamental
- Price
- BEST $2.78
- IMMX $1.76
- Analyst Decision
- BEST
- IMMX Strong Buy
- Analyst Count
- BEST 0
- IMMX 1
- Target Price
- BEST N/A
- IMMX $7.00
- AVG Volume (30 Days)
- BEST 33.2K
- IMMX 84.6K
- Earning Date
- BEST 03-26-2025
- IMMX 03-28-2025
- Dividend Yield
- BEST N/A
- IMMX N/A
- EPS Growth
- BEST N/A
- IMMX N/A
- EPS
- BEST N/A
- IMMX N/A
- Revenue
- BEST $1,183,106,017.00
- IMMX N/A
- Revenue This Year
- BEST N/A
- IMMX N/A
- Revenue Next Year
- BEST N/A
- IMMX $600.00
- P/E Ratio
- BEST N/A
- IMMX N/A
- Revenue Growth
- BEST 11.57
- IMMX N/A
- 52 Week Low
- BEST $1.85
- IMMX $1.26
- 52 Week High
- BEST $2.81
- IMMX $3.80
- Technical
- Relative Strength Index (RSI)
- BEST 73.75
- IMMX 31.71
- Support Level
- BEST $2.76
- IMMX $1.85
- Resistance Level
- BEST $2.81
- IMMX $2.14
- Average True Range (ATR)
- BEST 0.03
- IMMX 0.12
- MACD
- BEST 0.00
- IMMX -0.02
- Stochastic Oscillator
- BEST 69.31
- IMMX 8.43
About BEST BEST Inc. each representing twenty (20)
BEST Inc is a supply chain company. It provides a New Retail platform that offers technology-enabled integrated solutions such as supply chain management, express delivery, freight, merchandise sourcing, cross-border supply chain, last-mile, financial and value-added services. The Group operates in the following operating segments, Supply chain management services, Freight, Global and Others. The Others category principally relates to cross-border logistic coordination services. The majority of revenue generated from Freight segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.